Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.67 |
| ▸ | MLYCD | O95822 | 2/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15452545 | 0.85 | MAPK14 (0.67) | MAPK14MLYCDPTGS2HSP90AA1SRC | |
| SCHEMBL4332740 | 0.85 | MAPK14 (0.62) | MAPK14MLYCDPTGS2NPC1RAB9A | |
| SCHEMBL27744977 | 0.83 | TP53 (0.60) | MAPK14MLYCDHSP90AA1NPC1RAB9A | |
| SCHEMBL1882263 | 0.83 | MAPK14 (0.70) | MAPK14MLYCDPTGS2HSP90AA1NPC1 | |
| SCHEMBL4341533 | 0.83 | MAPK14 (0.72) | MAPK14MLYCDPTGS2NPC1RAB9A | |
| SCHEMBL4330105 | 0.82 | MAPK14 (0.58) | MAPK14MLYCDHSP90AA1NPC1RAB9A | |
| SCHEMBL4338190 | 0.82 | MAPK14 (0.66) | MAPK14MLYCDPTGS2HSP90AA1 | |
| SCHEMBL4342202 | 0.80 | MAPK14 (0.53) | MAPK14MLYCDPTGS2HSP90AA1NPC1 | |
| SCHEMBL6102776 | 0.80 | MAPK14 (1.00) | MAPK14MLYCDSRCBRAFKDR | |
| SCHEMBL4333467 | 0.80 | MAPK14 (0.72) | MAPK14MLYCDPTGS2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885MLYCD 4475/4885PTGS2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.